河南太龙药业股份有限公司为下属子公司融资提供担保的公告全解析
一、公告背景与主要内容
河南太龙药业股份有限公司（证券代码：600222，简称：太龙药业）于2026年5月29日发布公告，详细披露了为下属全资及控股子公司融资提供担保的最新情况。本次公告涉及三项重要担保，均为支持公司控股及全资子公司的经营发展和融资需求。
- 担保对象及金额：
- 北京新领先医药科技发展有限公司（控股子公司）：担保额度3,000万元，与宁波银行北京分行签署《最高额保证合同》。实际担保余额已达17,156万元。
- 浙江桐君堂中药饮片有限公司（全资子公司）：担保额度2,000万元，与中国农业银行桐庐县支行签署《保证合同》。实际担保余额为13,120万元。
- 北京新领先医药科技发展有限公司（控股子公司）：拟与永赢金融租赁有限公司签署《最高额保证合同》担保额度2,000万元。
- 累计担保情况：
- 公司及控股子公司对外担保总额为34,413.05万元，占公司最近一期经审计净资产的21.45%。
- 无逾期担保，未对控股股东或实际控制人及其关联人提供担保。
二、担保协议详细内容
本次担保均采用连带责任保证方式，担保范围涵盖主合同项下的主债权本金、利息、逾期利息、复利、罚息、违约金、损害赔偿金、实现债权的相关费用等。各项担保均无反担保安排，保证期间多为主合同债务履行期限届满后两年或三年。此举体现公司对下属子公司经营及债务风险的高度控制和管理能力。
三、被担保公司基本情况与财务状况
- 北京新领先医药科技发展有限公司：
- 公司持股87.38%，河南京港先进制造业股权投资基金持股12.62%。
- 2026年3月31日资产总额54,157.57万元，负债总额20,837.08万元，资产净额33,364.70万元。
- 2026年一季度营业收入4,085.60万元，净利润-561.70万元（2025年度净利润为1,920.85万元）。
- 浙江桐君堂中药饮片有限公司：
- 由桐君堂药业有限公司全资持股。
- 2026年3月31日资产总额54,072.06万元，负债总额30,352.34万元，资产净额23,719.72万元。
- 2026年一季度营业收入12,960.35万元，净利润783.23万元（2025年度净利润为3,080.06万元）。
两家公司均未被列入失信被执行人名单，资信情况良好。
四、董事会意见与风险提示
董事会认为，本次担保符合公司整体利益和发展战略，有助于提升公司整体融资效率，促进业务开展。公司对子公司风险及决策能有效控制，被担保公司财务状况稳定，整体风险可控。公告明确未出现逾期担保、未对控股股东及实际控制人担保、未出现重大风险提示。
五、对投资者和股价的影响分析
- 公司最新对外担保总额达到34,413.05万元，占净资产21.45%，仍处于合理范围内，未触及50%、100%等重大风险提示。
- 担保对象均为公司合并报表范围内的全资及控股子公司，且经营、财务状况良好，未出现失信等风险。
- 本次担保有助于支持子公司发展，提高整体融资效率，长期利好公司业绩及业务扩展。
- 无重大超额担保、无关联方担保、无逾期担保事项，显示公司风险管理能力较强。
六、投资者须知及可能的价格敏感事项
投资者需关注公司对外担保总额变化，特别是未来新增担保额度及被担保公司经营情况。公司担保总额占净资产比例仍处于可控范围内，但持续关注子公司经营状况和担保风险，若未来出现大额逾期担保或担保比例急剧上升，可能对公司财务及股价产生影响。目前担保行为为业务扩展支持，风险可控，整体利于公司发展。
免责声明
本文内容仅为信息解读，不构成任何投资建议。投资者应根据自身风险偏好和判断，审慎决策。公司实际经营及担保风险仍需持续关注。
English Version
Henan Tailong Pharmaceutical (600222) Subsidiary Financing Guarantee Announcement: Key Details
1. Background & Main Content
Henan Tailong Pharmaceutical Co., Ltd. (stock code: 600222, “Tailong Pharmaceutical”) released an announcement on May 29, 2026, detailing its latest guarantees for financing needs of its wholly-owned and controlled subsidiaries. The announcement covers three major guarantees, all designed to support operational and financing needs of key subsidiaries.
- Guarantee Targets & Amounts:
- Beijing Xinlingxian Pharmaceutical Technology Development Co., Ltd. (controlled subsidiary): Guarantee limit RMB 30 million, signed with Ningbo Bank Beijing Branch. Total actual guarantee balance: RMB 171.56 million.
- Zhejiang Tongjuntang Chinese Herbal Slices Co., Ltd. (wholly-owned subsidiary): Guarantee limit RMB 20 million, signed with Agricultural Bank of China, Tonglu Branch. Actual guarantee balance: RMB 131.2 million.
- Beijing Xinlingxian Pharmaceutical Technology Development Co., Ltd. (controlled subsidiary): Planned guarantee with Yongying Financial Leasing Co., Ltd., RMB 20 million.
- Cumulative Guarantee Situation:
- Total external guarantee amount by the company and its subsidiaries: RMB 344.13 million, accounting for 21.45% of the company’s latest audited net assets.
- No overdue guarantees; no guarantees for controlling shareholders or related parties.
2. Details of Guarantee Agreements
All guarantees use joint liability guarantee; the scope covers principal, interest, overdue interest, compound interest, penalty interest, damages, costs for realization, etc. No counter-guarantee arrangements. Guarantee periods are generally two or three years after the principal contract expires. This reflects the company’s high control over subsidiary operations and debt risks.
3. Subsidiary Information & Financial Status
- Beijing Xinlingxian Pharmaceutical Technology Development Co., Ltd.:
- Company holds 87.38% equity; Henan Jinggang Advanced Manufacturing Equity Investment Fund holds 12.62%.
- As of March 31, 2026: total assets RMB 541.58 million, liabilities RMB 208.37 million, net assets RMB 333.65 million.
- Q1 2026 revenue RMB 40.86 million, net loss RMB -5.62 million (2025 net profit RMB 19.21 million).
- Zhejiang Tongjuntang Chinese Herbal Slices Co., Ltd.:
- Wholly owned by Tongjuntang Pharmaceutical Co., Ltd.
- As of March 31, 2026: total assets RMB 540.72 million, liabilities RMB 303.52 million, net assets RMB 237.20 million.
- Q1 2026 revenue RMB 129.60 million, net profit RMB 7.83 million (2025 net profit RMB 30.80 million).
Both companies are not listed as “dishonest persons subject to enforcement”, and have sound credit.
4. Board Opinion & Risk Tips
The Board considers these guarantees necessary for subsidiary operational development, aligned with overall company interests and strategic plans. Risks are controllable, subsidiaries are financially stable, and there are no overdue or related-party guarantees. The company retains effective control over decision-making and day-to-day management.
5. Investor Impact & Price Sensitivity Analysis
- Total guarantee amount reaches RMB 344.13 million, 21.45% of net assets, still within reasonable risk range (no risk trigger thresholds).
- Guarantees are for consolidated subsidiaries with good financial health, no credit risks.
- Guarantees support expansion and financing, likely positive for long-term business and performance.
- No major over-guarantees, no related-party or overdue guarantees, indicating strong risk management.
6. What Investors Should Watch
Investors should monitor changes in guarantee amounts, future new guarantees, and subsidiary performance. While current guarantee ratio is controlled, rapid increases or significant overdue guarantees could impact financials and share price. Currently, guarantees support business growth and are risk-controlled.
Disclaimer
This article is for informational analysis only and does not constitute investment advice. Investors should make independent decisions based on their own risk tolerance and judgment. Actual business and guarantee risks require ongoing attention.
